# Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

> **NCT05909943** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Tianjin Medical University General Hospital**

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder Relapse

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05909943
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** We are doing a clinical study of Baritinib in Neuromyelitis Optica Spectrum Disorders, similar to this one, so the study was withdrawn.
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909943, "Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05909943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*